RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.

Understanding the Impact of Migraine

Lilly survey results point to need for new headache treatments.

A PPM Brief

Eli Lilly and Company (Indianapolis), received FDA approval to review the biologic galcanezumab—a once-monthly self-injection—for the prevention of adult migraine late last year, and has now released the results of its Migraine Impact Report. The report shares results of more than 1,000 adults surveyed across the US in 2017, including 518 diagnosed with migraine.1

Among those surveyed, those diagnosed with migraine reported experiencing 15.4 pain-free days on average over the previous 30 days. Symptoms prevented subjects from carrying out desired tasks for one week (6.9 days) on average over the same 30 days. The full report https://investor.lilly.com/releasedetail.cfm?ReleaseID=1057930 addresses how migraines impact patients’ careers, family life, and stress levels. A few findings from the report regarding public understanding of chronic headaches are highlighted below.1

  • Nearly all respondents diagnosed with migraine (91%) agreed that those who do not suffer from migraine do not understand the severity of the disease.
  • 62% of those surveyed who were diagnosed with migraine agreed that they try to hide the true impact of migraine from those at work or at school.
  • On a scale of one to 10, those surveyed who did not know someone with migraine underestimated their pain level  
  • 81% of respondents diagnosed with migraine agreed they wish they could do more to manage their disease
  • Among those who have a close relationship with someone with migraine, three out of four respondent agreed they would like this person to seek better care or treatment for their migraine.

"These findings shine a spotlight on the serious need for additional treatment options for the more than 36 million Americans battling with migraine, many of whom lack a treatment option that addresses their symptoms and allows them to function in their day-to-day lives or which is tolerable for them," said Dr. Timothy R. Smith, MD, RPh, FACP, vice president of National Headache Foundation in the Lilly release.1

 

 

 

Last updated on: March 29, 2018
Continue Reading:
Galcanezumab Appears Effective in Preventing Migraines
SHOW MAIN MENU
SHOW SUB MENU